Trial · NCT05320523
Simultaneous DBS of the GPi and the NBM in Patients With Parkinson's Disease and Mild Cognitive Impairment
NCT05320523, Not applicable, Unknown, University of Sao Paulo General Hospital
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Simultaneous DBS of the GPi and the NBM in Patients With Parkinson's Disease and Mild Cognitive Impairment. Trials, record NCT05320523. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT05320523
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Simultaneous DBS of the GPi and the NBM in Patients With Parkinson's Disease and Mild Cognitive Impairment
- NCT number
- NCT05320523
- Status
- Unknown
- Phases
- Not applicable
- Enrollment
- 10 participants, estimated
- Lead sponsor
- University of Sao Paulo General Hospital
- Conditions
- Parkinson Disease, Mild Cognitive Impairment
- Interventions
- Deep brain stimulation implantation of a Vercise neurostimulation system in GPi and NBM., GPi stimulation, NBM stimulation, Sham stimulation
- First posted
- 2022-04-11
- Last updated
- 2022-04-11
Source ClinicalTrials.gov
Registered outcomes28
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Safety of combined bilateral Globus Pallidus internus (GPi) and Nucleus Basalis of Meynert (NBM) stimulation in patients with moderate to advanced Parkinson's disease with mild cognitive impairment as determined by reported adverse events. | 36 weeks | Safety of combined bilateral GPi and NBM stimulation in patients with moderate to advanced Parkinson's disease having mild cognitive impairment as determined by reported adverse events. |
| Secondary | Change in Parkinson's Disease - Cognitive Rating Scale (PD-CRS). | 36 weeks | This scale can range from 0 to 134, and higher scores mean a better outcome. |
| Secondary | Change in Mattis Dementia Rating Scale. | 36 weeks | This scale can range from 0 to 144, and higher scores mean a better outcome. |
| Secondary | Change in Verbal Fluency Battery. | 36 weeks | FAS and animals |
| Secondary | Change in Trail Making Task. | 36 weeks | Trail Making Task Part A + B. |
| Secondary | Change in Stroop Test. | 36 weeks | Stroop Test (Victoria Version). |
| Secondary | Change in Symbol Digit Modalities Test. | 36 weeks | Digit symbol coding - WAIS. |
| Secondary | Change in Parkinson's Disease Questionnaire for quality of life (PDQ-39). | 36 weeks | This questionnaire can range from 0 to 100%, and higher scores mean a worse outcome. |
| Secondary | Change in Questionnaire of the EuroQol-group (EQ-5D-5L). | 36 weeks | This questionnaire can range from 0 to 25, and higher scores mean a worse outcome. |
| Secondary | Change in Unified Parkinson's Disease Rating Scale section I (UPDRS I). | 36 weeks | This scale can range from 0 to 52, and higher scores mean a worse outcome. |
1 to 10 of 28Source ClinicalTrials.gov
See all 28 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers10
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests4
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|---|---|
| Stroop Color-Word Test | Secondary outcome | ConductCognition |
| Symbol Coding | Secondary outcome | ConductCognition |
| Trail Making Test A | Secondary outcome | ConductCognition |
| Verbal Fluency | Secondary outcome | ConductCognition |
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT05320523
GET https://conductscience.org/api/trials/v1/NCT05320523/registered?page=2